x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

DarshanTalks Podcast

Darshan Kulkarni

Welcome to DarshanTalks!We demystify fraud for legal, regulatory, and compliance essentials in the life sciences and pharmacy industries. Through engaging 15-30-minute interviews with influential change makers, short educational regulatory defbriefs, and 60 second audio takeaways, we unveil the strategies behind bringing drugs and devices to market—and keeping them there!Powered By The Kulkarni Law Firm - Helping regulators see your business the way you do.We focus on life science issues involving

science life sciences

All Episodes

2:38

Sponsor to Organization vs. Direct Investigator...

DarshanTalks Podcast ·

2025/03/31

Edye Edens from KLF highlights the key differences between sponsor-to-organization agreements and direct investigator agreements. Larger research organizations and academic medical centers often prefer sponsor-to-organization agreements because they provide structured negotiations around intellectual property (IP) rights, indirect costs, liability protections, and compliance oversight. These agreements also ensure that investigators have access to institutional resources and support. On the o...

en-us

4:20

Clinical Trial Site M&A: What Most Get Wrong

DarshanTalks Podcast ·

2025/03/29

Most clinical trial site mergers focus on patient databases, sponsor contracts, and geographic expansion. While those are important, the real risks lie elsewhere—buried in compliance issues that can derail your deal before it even closes. Imagine acquiring a site that looks great on paper, only to face FDA or DOJ scrutiny months later due to undisclosed 483s, protocol deviations, or even kickback violations. Instead of scaling operations, you're dealing with regulatory investigations and pote...

en-us

8:38

Future-Proof Sites: SOS Insights Revealed

DarshanTalks Podcast ·

2025/03/27

In this episode, Darshan Kulkarni sits down with Raymond Nomizu, founder and co-CEO of CRIO, to discuss key takeaways from the SOS conference and the evolving landscape of clinical research. Raymond shares his journey from running a clinical research site to founding CRIO, a platform designed to modernize site operations through eSource, CTMS, and real-time data solutions. They explore major industry trends, including the rise of site networks, increasing sponsor demand for real-time data acc...

en-us

2:29

Why Food M&A Deals Collapse—And How to Prevent It

DarshanTalks Podcast ·

2025/03/25

Darshan talks about a major blind spot in food M&A—hidden compliance risks that can destroy a deal overnight. While most focus on financials, market share, and synergies, they fail to account for regulatory pitfalls that can trigger investigations, recalls, or severe penalties. Imagine being deep in negotiations, only to discover unapproved ingredients, misleading health claims, or an undisclosed FDA warning letter buried in company files. Some executives make the mistake of pushing forwa...

en-us

2:00

Non-Compliance Led to QOL Medical's $47M Settlement

DarshanTalks Podcast ·

2025/03/23

The recent $47 million settlement involving QOL Medical and its CEO is a stark reminder of the consequences of crossing legal and ethical boundaries. Allegations of offering free Carbon 13 breath test kits as kickbacks to induce prescriptions for Sucraid, a treatment for congenital sucrose isomaltase deficiency (CSID), aren't just about non-compliance—they’re about patient safety. The breath tests could not specifically diagnose CSID but were marketed as such, leading to inappropriate prescri...

en-us

2:52

FDA Regulatory Submissions: Challenges, Trends, and...

DarshanTalks Podcast ·

2025/03/21

Edye Edens from KLF offers a brief yet in-depth overview of FDA regulatory submissions for clinical research in the U.S., reflecting on both current practices and predictions for 2025. She highlights how AI tools and evolving political dynamics are shaping the regulatory landscape, emphasizing that while efficiency improvements are necessary, careful and strategic approaches are critical to maintain the FDA’s global reputation and safety standards. Edye discusses the complexity of submissions...

en-us

14:42

How to do a VR promo check - Carly Schaecter gives us...

DarshanTalks Podcast ·

2025/03/19

Carly Schaechter discusses the potential of VR in drug promotion and the challenges of reviewing VR content for the PRC. Key points include the need for VR expertise to conceptualize interactive, engaging content. Choosing VR over AR depends on the objectives, with VR offering more controlled environments. Ensuring user control, addressing misinformation, and learning from past mistakes are crucial for successful VR implementation. Gamification and user experience evaluation are critica...

en-us

5:42

Diversity Matters in Clinical Trials

DarshanTalks Podcast ·

2025/03/18

In this insightful discussion, Shuja Naqvi, CEO of Biopharma Informatics, joins Darshan Kulkarni to explore the evolving landscape of clinical research. Shuja shares how his company has expanded across seven states, strategically choosing locations to promote diversity—not just in ethnicity, but also in socioeconomic and regional representation. He highlights the importance of gathering data from various populations to improve the effectiveness and inclusivity of clinical trials. They delve i...

en-us

2:44

EMA’s LLM Guidelines Impact Life Sciences

DarshanTalks Podcast ·

2025/03/16

The EMA's new guiding principles on LLMs represent a transformative step in regulatory science, addressing both the immense potential and significant risks of these technologies. These principles emphasize the need to balance innovation with ethical considerations, tackling issues like data privacy, misinformation, and bias. LLMs, such as ChatGPT, hold promise for automating workflows like medical translations, pharmacovigilance reporting, and coding support. However, the EMA stresses continu...

en-us

17:08

How to Network Like a Pro at Conferences

DarshanTalks Podcast ·

2025/03/12

In this episode, Darshan sits down with Brook White from CRIO to dive into the value of attending conferences and how to make the most of them. They met at a past conference and quickly realized how much we had to learn from each other, so I asked Brook to come on and share her insights. They start by discussing whether conferences are truly valuable—considering the costs, time investment, and potential for networking. While online learning can be beneficial, conferences offer unique opportun...

en-us

10:35

Getting Ready for SOS 2025: FDA 483s, SOPs, and Site...

DarshanTalks Podcast ·

2025/03/10

In this conversation, Edye Edens and Darshan Kulkarni discuss the excitement and plans for the upcoming Save Our Sites (SOS) Second Annual Conference in Oklahoma City. They highlight the importance of connecting with key industry leaders and peers in person, including names like Dan Sfera, Brad Hightower, and others who have been instrumental voices in the clinical research space. Darshan shares that Kulkarni Law Firm (KLF) will be participating and is excited to engage with attendees, talk a...

en-us

2:13

Maximizing Site Value

DarshanTalks Podcast ·

2025/03/07

When selling a clinical trial site, many owners focus solely on the amount they’ll receive, but the real key is understanding the multiplier that determines your valuation. In M&A transactions, hitting the right EBITDA threshold—such as $3M, $10M, or $25M—can significantly increase your multiplier, turning a 6X valuation into 10X or more. While some claim multipliers as high as 26X, the reality is more complex. Beyond valuation, choosing the right private equity partner is just as critica...

en-us

3:33

5 Key Areas to Review in Clinical Trial Agreements

DarshanTalks Podcast ·

2025/03/05

Contract issues are more common than you think. Edye Edens shares the five critical areas you should always review before signing: Basic Details & Formatting – Ensure names, dates, and references are correct, pages are in order, and there are no typos or inconsistencies from previous templates.Appendices & Exhibits – Verify that referenced documents, such as addendums, exhibits, and budgets, are included and properly linked to the contract.Budget & Payment Terms – Clarify payment ...

en-us

7:43

Discussing Stem Cell Research Opportunities with a...

DarshanTalks Podcast ·

2025/03/03

At the Site Council meeting, Darshan Kulkarni had the opportunity to speak with Mohamed Hakim, a site owner who has consolidated six clinical research sites into three. Their conversation explored the evolving landscape of clinical research, particularly in stem cell studies, in light of the regulatory shifts happening under the Trump administration. Mohamed highlighted the increasing number of clinical trials and the expansion of pharmaceutical research into Europe, creating new opportunitie...

en-us

6:23

Quality Management: A Must in Clinical Trial Contracts

DarshanTalks Podcast ·

2025/03/01

In the second part of our discussion, Edye Edens speaks with subject matter expert Helen Maurer about integrating quality management into clinical trial contracts. While contracts often cover legal aspects like termination and jurisdiction, they frequently lack clear quality management plans. Helen emphasizes the importance of defining responsibilities, risk levels, and monitoring expectations upfront to avoid confusion and compliance issues later. Key takeaways: Contracts should outline qual...

en-us

5:29

AI-Powered Chatbots in Pharma Sales and Education

DarshanTalks Podcast ·

2025/02/27

ChatGPT's recent update introduced an AI engagement feature reminiscent of the movie Her, the conversation is highly relevant as AI becomes more integrated into daily business operations. While AI voice chat offers benefits like consistent messaging, 24/7 availability, and efficiency, it also brings significant risks—especially in the heavily regulated pharmaceutical and medical device sectors. The episode explores key challenges, starting with privacy and security concerns. AI-enabled system...

en-us

1:21

Will New Tariffs Disrupt Your Next Pharma Deal?

DarshanTalks Podcast ·

2025/02/26

The proposed 25% tariff on pharmaceutical APIs from China could have far-reaching effects on M&A transactions within the life sciences and healthcare industries. Since a significant portion of pharmaceutical raw materials originate in China, companies may face increased costs not only in sourcing but also in sales, as Canada considers imposing its own tariffs. This could disrupt global supply chains, making due diligence even more critical for buyers evaluating international pharmaceutica...

en-us

5:10

Protecting Patient Data in a Changing Regulatory...

DarshanTalks Podcast ·

2025/02/25

In this discussion, Edye Edens and Helen Maurer dive into the critical topic of data privacy and security in clinical research, particularly in light of potential federal oversight. Helen, an expert in compliance and quality assurance within oncology research, emphasizes the need for clinical trial sites—especially those at major academic medical centers—to understand whether their privacy regulations fall under state or federal jurisdiction. They explore hypothetical scenarios where federal ...

en-us

31:17

Off-Label Promotion Changes in 2025

DarshanTalks Podcast ·

2025/02/24

Stephanie Trunk and Darshan Kulkarni discuss the evolving landscape of the pharmaceutical industry under the Trump Administration in 2025. They highlight the uncertainty surrounding regulatory changes, particularly with new leadership at the FDA, CMS, and HHS (with RFK confirmed). There is concern over shifting prosecutorial priorities, overturned FDA diversity initiatives, and potential scrutiny of diversity efforts in private companies. A major focus is the changing environment of off-label...

en-us

16:23

Turning Physicians into Leaders

DarshanTalks Podcast ·

2025/02/21

Kate Woods interviews Lee Scheinbart, who shares valuable advice for physicians aspiring to become Chief Medical Officers (CMOs) or take on leadership roles in healthcare. Lee stresses the importance of being intentional in career decisions and encourages young physician leaders to first focus on becoming competent clinicians. He advises earning medical degrees, completing training, and gaining clinical experience for 5 to 10 years before transitioning into leadership. Lee also discusses the ...

en-us

331 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter